SCHEMBL356392

SCHEMBL356392

CC(C)=CCCC(C)=CC(O)O

nearest known ligand 0.58

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.58
MEN1 O00255 2/20 0.54
CYP3A4 P08684 2/20 0.54
ALOX15 P16050 2/20 0.54
MAPT P10636 2/20 0.52
ALDH1A1 P00352 2/20 0.52
UGT1A1 P22309 1/20 0.52
SQLE Q14534 5/20 0.50
KDM4E B2RXH2 3/20 0.48
ATM Q13315 1/20 0.48
FNTA P49354 1/20 0.47
FNTB P49356 1/20 0.47
POLB P06746 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11584608 1.00 KMT2A (0.58) KMT2AMEN1CYP3A4ALOX15MAPT
SCHEMBL11586065 1.00 KMT2A (0.58) KMT2AMEN1CYP3A4ALOX15MAPT
Water SCHEMBL9280359 0.98 KMT2A (0.56) KMT2AMEN1CYP3A4ALOX15MAPT
SCHEMBL6664660 0.96 KMT2A (0.67) KMT2AMEN1CYP3A4ALOX15MAPT
SCHEMBL808086 0.84 KMT2A (0.56) KMT2AMEN1CYP3A4ALOX15MAPT
SCHEMBL1616971 0.84 KMT2A (0.56) KMT2AMEN1CYP3A4ALOX15MAPT
SCHEMBL1617090 0.84 KMT2A (0.56) KMT2AMEN1CYP3A4ALOX15MAPT
SCHEMBL795270 0.82 KMT2A (0.54) KMT2AMEN1CYP3A4ALOX15MAPT
SCHEMBL7687531 0.82 KMT2A (0.54) KMT2AMEN1CYP3A4ALOX15MAPT
SCHEMBL30560064 0.82 KMT2A (0.54) KMT2AMEN1CYP3A4ALOX15MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117982698-A Vehicle-mounted fragrance and preparation method thereof 广州汽车集团股份有限公司 2024-05-07 CN claimed
US-6506793-B2 For sustained release of lemon aroma unique to citral; perfumes; leucine dehydrogenase inhibitors; deodorants, cosmetics, dermatology agents KAO CORPORATION (JP) 2003-01-14 US claimed
US-20020068075-A1 Citral Acetal KAO CORPORATION (JP) 2002-06-06 US claimed
US-6239087-B1 COMPOSITIONS CONTAINING CERTAIN ACETALS OR KETALS WHICH HYDROLYZE UPON EXPOSURE OF SURFACES WASHED IN SOLUTION OF SAID COMPOSITIONS TO REDUCTION IN PH, THEREBY RELEASING FRAGRANCE CHARACTERISTIC OF ONE OR MORE OF HYDROLYSIS PRODUCTS THE PROCTER & GAMBLE COMPANY 2001-05-29 US claimed
EP-0888439-A1 DETERGENT COMPOSITIONS CONTAINING FRAGRANCE PRECURSORS AND THE FRAGRANCE PRECURSORS THEMSELVES THE PROCTER & GAMBLE COMPANY (US) 1999-01-07 EP claimed
WO-1997034986-A1 DETERGENT COMPOSITIONS CONTAINING FRAGRANCE PRECURSORS AND THE FRAGRANCE PRECURSORS THEMSELVES THE PROCTER & GAMBLE COMPANY (US) 1997-09-25 WO claimed
US-5466721-A Citral acetal ethers of alpha-hydroxy phenyl ketones and radiation curable compositions thereof HENKEL CORPORATION (US) 1995-11-14 US claimed
WO-1994029355-A1 CITRAL ACETAL ETHERS OF ALPHA-HYDROXY PHENYL KETONES AND POLYMERIZABLE COMPOSITIONS HENKEL CORPORATION (US) 1994-12-22 WO claimed
US-4832059-A ADDING CITRAL ACETAL AND AGING LORILLARD, INC. (US) 1989-05-23 US claimed
CN-118076767-A Method and formulation for producing an optical metal oxide layer 默克专利有限公司 2024-05-24 CN disclosed
CN-117982698-A Vehicle-mounted fragrance and preparation method thereof 广州汽车集团股份有限公司 2024-05-07 CN disclosed
US-20210330667-A1 TOPICAL COMPOSITION OF NALBUPHINE AND METHOD FOR TREATING PRURITUS CONDITION, PAIN, OR INFLAMMATORY CONDITION BY USING THE SAME LUMOSA THERAPEUTICS CO., LTD. (TW) 2021-10-28 US disclosed
US-20190002722-A1 FORMULATIONS CONTAINING A MIXTURE OF AT LEAST TWO DIFFERENT SOLVENTS MERCK PATENT GMBH (DE) 2019-01-03 US disclosed
EP-3390550-A1 FORMULATIONS CONTAINING A MIXTURE OF AT LEAST TWO DIFFERENT SOLVENTS Merck Patent GmbH (DE) 2018-10-24 EP disclosed
US-5426247-A CONDENSATION OF CYCLOGERANL SULFONE, HALOGENATION, REMOVING SULFONE AND HALOGN, DEACETALIZATION, ISOMERIZATION RHONE-POULENC NUTRITION ANIMALE (FR) 1995-06-20 US disclosed
WO-1994029355-A1 CITRAL ACETAL ETHERS OF ALPHA-HYDROXY PHENYL KETONES AND POLYMERIZABLE COMPOSITIONS HENKEL CORPORATION (US) 1994-12-22 WO disclosed
EP-0343234-A1 CITRUS-FLAVORED TOBACCO ARTICLES LORILLARD, INC. (US) 1989-11-29 EP disclosed
WO-1989005102-A1 CITRUS-FLAVORED TOBACCO ARTICLES LORILLARD, INC. (US) 1989-06-15 WO disclosed
US-4832059-A ADDING CITRAL ACETAL AND AGING LORILLARD, INC. (US) 1989-05-23 US disclosed
US-4832059-A ADDING CITRAL ACETAL AND AGING LORILLARD, INC. (US) 1989-05-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020068075-A1 Citral Acetal LDHA, LDHB, ALDH1A1 KMT2A 2545/4885MEN1 2261/4885CYP3A4 515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.